secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2026-09-08T20:41:28+00:00
Accession:  0001193125-26-385293
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase updates September 2026 corporate presentation; no new financial or pipeline details disclosed
--------------------------------------------------------------------------------

- Furnished updated corporate presentation dated September 2026 for investor, analyst, and other meetings.
- Reported September 8, 2026; signed by CEO Mark Iwicki.
- Available exhibit text contains only a standard disclaimer; no specific financials, pipeline data, or milestones included in filing excerpt.
- Presentation furnished under Regulation FD; common stock trades as IKT on Nasdaq.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312526385293/0001193125-26-385293-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312526385293/d152999d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-385293

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer